- Home
- CJET vs KPRX Comparison
CJET vs KPRX Comparison
Compare CJET & KPRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CJET
- KPRX
- Stock Information
- Founded
- CJET 2009
- KPRX 1998
- Country
- CJET China
- KPRX United States
- Employees
- CJET N/A
- KPRX N/A
- Industry
- CJET Auto Manufacturing
- KPRX Biotechnology: In Vitro & In Vivo Diagnostic Substances
- Sector
- CJET Consumer Discretionary
- KPRX Health Care
- Exchange
- CJET Nasdaq
- KPRX Nasdaq
- Market Cap
- CJET 8.3M
- KPRX 8.3M
- IPO Year
- CJET N/A
- KPRX N/A
- Fundamental
- Price
- CJET $1.96
- KPRX $3.20
- Analyst Decision
- CJET
- KPRX Strong Buy
- Analyst Count
- CJET 0
- KPRX 1
- Target Price
- CJET N/A
- KPRX $10.00
- AVG Volume (30 Days)
- CJET 185.7K
- KPRX 9.6K
- Earning Date
- CJET 05-06-2025
- KPRX 05-09-2025
- Dividend Yield
- CJET N/A
- KPRX N/A
- EPS Growth
- CJET N/A
- KPRX N/A
- EPS
- CJET N/A
- KPRX 0.87
- Revenue
- CJET $10,275,000.00
- KPRX $16,020,000.00
- Revenue This Year
- CJET N/A
- KPRX N/A
- Revenue Next Year
- CJET N/A
- KPRX N/A
- P/E Ratio
- CJET N/A
- KPRX $3.68
- Revenue Growth
- CJET 31.31
- KPRX N/A
- 52 Week Low
- CJET $1.09
- KPRX $2.51
- 52 Week High
- CJET $23.94
- KPRX $5.55
- Technical
- Relative Strength Index (RSI)
- CJET 59.07
- KPRX 62.37
- Support Level
- CJET $1.68
- KPRX $3.06
- Resistance Level
- CJET $2.00
- KPRX $3.29
- Average True Range (ATR)
- CJET 0.21
- KPRX 0.20
- MACD
- CJET 0.00
- KPRX 0.08
- Stochastic Oscillator
- CJET 78.25
- KPRX 88.46
About CJET Chijet Motor Company Inc.
Chijet Motor Co Inc is engaged in the research and development, production and sales of new energy vehicles. New energy vehicles refer to plug-in electric vehicles including battery electric vehicles, plug-in hybrid (PHEV) electric vehicles, and fuel cell electric vehicles. Its passenger vehicles include small cars, sedans, and sports utility vehicles, or SUVs, and commercial vehicles include light trucks and vans.
About KPRX Kiora Pharmaceuticals Inc.
Kiora Pharmaceuticals Inc is a clinical-stage biotechnology company developing and commercializing products for the treatment of orphan retinal diseases. As part of its development, KIO-301 is being studied for the treatment of retinitis pigmentosa, choroideremia, and Stargardt disease. It is a molecular photoswitch that has the potential to restore vision in patients with inherited and/or age-related retinal degeneration. KIO-104 is being developed for the treatment of posterior non-infectious uveitis. It is a next-generation, non-steroidal, immuno-modulatory, and small-molecule inhibitor of dihydroorotate dehydrogenase.